Skip to main content

Table 4 Comparison of clinical outcomes during hospitalization between study groups

From: Real-world use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/β-blocks in Chinese patients before acute myocardial infarction occurs: patient characteristics and hospital follow-up

 

AAβ (n, %)

NO-AAβ (n, %)

p value

Overall population

 Number

872

1833

 

 MACE

69 (7.92)

108 (5.92)

0.049

 Cardiac-death

28 (3.21)

54 (2.96)

0.720

 All-cause death

29 (3.3)

62 (3.4)

0.939

 Target vascular reconstruction

1 (0.11)

0 (0)

0.148

 Recurrent myocardial infarction

39 (4.48)

45 (2.47)

0.005

 Malignant arrhythmia

2 (0.23)

2 (0.11)

0.451

 Cerebral infarction

3 (0.35)

7 (0.39)

0.874

 Cerebral hemorrhage

3 (0.35)

8 (0.44)

0.718

Matched population

 Number

226

452

 

 MACE

13 (5.75)

21 (4.65)

0.53

 Cardiac-death

8 (3.54)

12 (2.65)

0.631

 All-cause death

8 (3.54)

13 (2.88)

0.638

 Target vascular reconstruction

0 (0)

0 (0)

 

 Recurrent myocardial infarction

6 (2.65)

7 (1.55)

0.322

 Malignant arrhythmia

1 (0.44)

2 (0.44)

0.999

 Cerebral infarction

0 (0)

3 (0.67)

0.220

 Cerebral hemorrhage

0 (0)

4 (0.89)

0.157

  1. MACE = cardiac-death or target vascular reconstruction or recurrent myocardial infarction or malignant arrhythmia or cerebral infarction or cerebral hemorrhage
  2. MACE major adverse cardiovascular events